Poland· PL-100328039
Dermitopic
A tacrolimus product containing tacrolimusum, registered in Poland by Bausch Health Ireland Ltd.. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Tacrolimus is registered in 12 of 19 countries.
Countries holding a registration under ATC D11AH01 (tacrolimus), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Tacrolimus · ATC D11AH01
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Tacrolimusum
- Manufacturer
- Bausch Health Ireland Ltd.
- Country
- Poland (PL)
- ATC code
- D11AH01
- ATC class
- Tacrolimus
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin03830044949815
- gtin03830044949808
- gtin03830044949822
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tacrolimus in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandProtopicParanova Oy
- CzechiaPROTOPICLEO Pharma A/S, Ballerup
- CanadaPROTOPICLEO PHARMA INC
- IcelandProtopicLEO Pharma A/S*
- United StatesASTAGRAF XLAstellas Pharma US, Inc.
- SwedenAdoport 0,5 mg Kapsel, hårdMedartuum AB
- United KingdomAdoport 0.5mg capsulesSandoz Ltd
- NetherlandsAdport 0,5 mg, capsules, hardEuro Registratie Collectief B.V.
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Adport, Dailiport
- Belgium · Adoport, Dailiport
- Bulgaria · Програф
- Cyprus · Prograf, Tacrolimus Accord
- Czechia · Dailiport, Gecrol
- Germany · Crilomus, Dailiport
- Denmark · Adport, Dailiport
- Estonia · Dailiport, Lebsanan
- Spain · Adoport, Cellmune
- Finland · Adport, Adport,
- France · Adoport, Conferoport
- United Kingdom (Northern Ireland) · Adoport, Ascezo
- Greece · Atodrit-Dermo, Eczatope Derm
- Croatia · Atezyrix, Dermitopic
- Hungary · Prograf, Tacrolimus Stada
- Ireland · Prograf, Tacrolimus Accord
- Iceland · Advagraf, Dailiport
- Italy · Adoport, Carelimus
- Liechtenstein · Advagraf, Envarsus
- Lithuania · Dailiport, Lebsanan
- Luxembourg · Prograft, Sumilor
- Latvia · Dailiport, Lebsanan
- Malta · Prograf
- Netherlands · Adport, Conferoport
- Norway · Adport, Advagraf
- Portugal · Adoport, Dermitopic
- Romania · Prograf, Tacrolimus Sandoz
- Sweden · Adport, Adport,
- Slovenia · Adoport, Dailiport
- Slovakia · Atezyrix, Dailiport
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b37cc766-58f5-47c7-97b8-6d9ee4614975 GET /v1/drugs/b37cc766-58f5-47c7-97b8-6d9ee4614975?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Maść",
"source": "urpl",
"strength": "0,1%",
"packaging": "03830044949815 ¦ Rpz ¦ 126819\n1 tuba 30 g\n03830044949808 ¦ Rpz ¦ 126820\n1 tuba 10 g\n03830044949822 ¦ Rpz ¦ 126821\n1 tuba 60 g",
"substance": "Tacrolimusum monohydricum 1.022 mg/g",
"common_name": "Tacrolimusum",
"pl_product_id": "100328039",
"pozwolenie_nr": "24671",
"auth_procedure": "DCP",
"authorisation_validity": "Bezterminowe"
}See everything about tacrolimus.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.